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The main purpose of the present review article was to shed light on the different 5-fluorouracil (5-FU) prodrugs by underlining their
respective pharmacological features in terms of metabolic activation, dihydropyrimidine dehydrogenase inhibition, pharmacokinetic
profile and biomodulation ability. Oral fluoropyrimidines differ particularly as concerns their pharmacokinetic profile and especially in
the delivery of circulating 5-FU. More clinical studies need to be performed incorporating tumour predictive markers during oral
fluoropyrimidine-based treatment. The new possibilities are to achieve pharmacomodulation of oral fluoropyrimidines, notably for
UFT and capecitabine, that open up the prospect of establishing significant novel treatment protocols based on drug combinations.
British Journal of Cancer (2004) 91, 613–617. doi:10.1038/sj.bjc.6601973 www.bjcancer.com
Published online 27 July 2004
& 2004 Cancer Research UK
Keywords: oral chemotherapy; UFT; capecitabine
                                 
5-Fluorouracil (5-FU) remains one of the most commonly
prescribed anticancer drugs with significant activity against
cancers of the gastrointestinal tract, head and neck and breast.
Repeated intravenous administrations or protracted infusions are
heavy for patients. Other oral 5-FU prodrugs, with new
pharmacological characteristics, are now emerging in the clinical
area in oncology (Diasio, 1999). These 5-FU prodrugs differ
markedly in their mode of activation, their pharmacokinetic
behaviour, particularly in terms of dihydropyrimidine dehydro-
genase (DPD) inhibition, and their pharmacologic modulation.
Table 1 describes the 5-FU prodrugs currently at more or less
advanced stage of clinical development. Previous reviews on oral
fluoropyrimidines have provided extensive description of the
different characteristics of these drugs (Diasio, 1999). The purpose
of the present review is to propose a transversal pharmacological
analysis of these oral fluoropyrimidines. Thus, special attention
will be paid to metabolic activation, DPD inhibition, pharmaco-
kinetic profile and biomodulation ability leading to compare oral
fluoropyrimidines between them at the light of these latter
pharmacological criteria. This information could promote a better
understanding of their pharmacological properties as well as
enabling optimal clinical use in the framework of the currently
approved therapeutic schedules and in the context of future
clinical developments.
DPD INHIBITION
More than 80% of an administered dose of 5-FU is eliminated by
catabolism through DPD which is the rate-limiting enzyme of
pyrimidine catabolism (Grem, 1996). The combination of DPD
inhibitors with 5-FU itself or 5-FU prodrugs has several potential
pharmacologic benefits conferred by the inhibition of 5-FU
catabolism during gastrointestinal absorption and first pass in
the liver. Furthermore, DPD inhibition improves pharmacokinetic
behaviour of delivered 5-FU by reducing interpatient variability
and by increasing 5-FU half-life. This latter benefit is particularly
useful in limiting repeated oral administrations of the drug which
is uncomfortable for patients. A large spectrum of DPD inhibitors
are used in combination with 5-FU or 5-FU prodrugs. At one
extreme, there is eniluracil, which has no cytotoxic activity but
which constitutes the most efficacious DPD inhibitor, acting by
DPD inactivation through the formation of a covalent bond; this
covalent reaction irreversibly inhibits DPD activity at its active
site. At the other extreme is UFT including uracil (U) which is a
simple competitive inhibitor of DPD activity since it is the natural
substrate of DPD. S-1 incorporates another DPD competitor, 5-
chloro-2,4-dihydroxypyridine which is 200-fold more potent than
U (Shimasaka et al, 1996). BOF-A2 is an oral prodrug of 5-FU and
3-cyano-2,6-dihydropyrimidine (CNDP). BOF-A2 is rapidly trans-
formed by esterification into two 1:1 components, namely, 1-
ethoxymethyl-5-fluorouracil and CNDP. CNDP is also a competi-
tive inhibitor of DPD with a potency of 2000 times greater than
that of U (Tatsumi et al, 1993). Capecitabine does not incorporate
a DPD inhibitor and is converted to the cytotoxic moiety 5-FU in
target tissue through a series of three metabolic steps (Diasio,
1999). The development of the compound RO0094889 which
generates the DPD inhibitor 5-vinyluracil preferentially in tumours
by the same enzymes as in capecitabine activation (Hattori et al,
2003) may lead to an interesting combination RO0094889–
capecitabine to be further explored at the clinical level (Endo
et al, 2003).
PHARMACOKINETICS
Oral fluoropyrimidines differ particularly as concerns their
pharmacokinetic profile and especially in the delivery of circulat-
ing 5-FU. The DPD inactivator eniluracil is administered with 5-FU
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www.bjcancer.comin a 10:1 ratio and produces 5-FU directly in the blood
compartment. 5-FU pharmacokinetics during multiple oral dosing
of eniluracil and 5-FU have been reported by Baker et al (2000).
Elimination half-life of 5-FU was around 4.0h. Between day 2 and
day 29 the main pharmacokinetic parameters remained constant,
notably for the values of the total body clearance (Baker et al,
2000). Interestingly, Adjei et al (2002) recently reported on a
randomised, open-label, cross-over study comparing continuous
venous infusion (CVI) of 5-FU to 5-FU/eniluracil combination.
The authors noted that individual 5-FU concentrations during CVI
were highly variable whereas those after 5-FU/eniluracil were more
reproducible, this lesser variability in 5-FU concentrations
following 5-FU/eniluracil being attributable to the inhibition of
DPD.
The pharmacokinetics of 5-FU following the administration of
S-1 at a standard dose of 80mgm
 2day
 1 were first reported by
Hirata et al (1999). This relative stability in the pharmacokinetics
of 5-FU during S-1 treatment was not in agreement with the recent
data by Peters et al (2003), who reported an increase in 5-FU and
uracil plasma concentration during repeated daily administration
of S-1. Thus, more data are needed about the time-stability of the
pharmacokinetics of S-1 during repeated administration. Elimina-
tion half-life of 5-FU during S-1 treatment was reported to be in
the range of 1.9–2.9h (Hirata et al, 1999). This slowed 5-FU
elimination as compared to 5-FU given alone reflects the presence
of the DPD inhibitor in S-1. The fate of 5-FU following the
administration of BOF-A2 was examined during a phase I dose-
escalating trial (200mgm
 2day
 1 b.i.d. to 300mgm
 2day
 1 t.i.d.,
Nemunaitis et al, 2000). The mean steady-state concentration of
plasma 5-FU was in the range of 30–100ngml
 1. A lack of
variation of 5-FU through levels within a day at steady state could
be explained by the suppression of circadian variations in 5-FU
concentrations due to the DPD inhibition (Petit et al, 1988).
Average plasma concentrations of 5-FU generated from FT in
patients treated with oral UFT were comparable to those observed
in CVI-treated patients (Ho et al, 1998). Owing to the presence of
uracil the 5-FU elimination half-life was markedly higher during
UFT treatment (7.273.9h on day 5) as compared to CVI (0.19h).
Muggia et al (1996) examined 5-FU AUC levels as a function of the
timed dose of UFT, 300mgm
 2 (0800 vs 1800h). Although not
significant, higher 5-FU blood exposures (AUC) were observed in
the afternoon dose as compared to the morning. The fact that
patients were not their own controls limits the conclusions of the
latter study but, from a practical point of view, it would be
particularly important to know the magnitude of the difference in
5-FU availability between morning and afternoon administration
of UFT. A study was undertaken to address the possible
pharmacokinetic influence of concurrent oral administration of
UFT and LV (Meropol et al, 1999). When LV was coadministered
with UFT, there was no significant impact on the fates of FT, uracil
and, particularly, on 5-FU AUC values. Urien et al (2003) recently
examined intrapatient variations in the UFT pharmacokinetics on
the first cycle of treatment. A steady state was attained for FT and
5-FU at least on day 8 and there was no further cumulative increase
in the AUC of these compounds after 1 week of treatment. In
contrast, Ho et al (2000) noted that repeated treatment with UFT
led to more or less marked cumulative increase in most of the
clinically relevant pharmacokinetic parameters. Thus, larger
clinical pharmacokinetic studies are still needed to examine more
thoroughly the evolution of 5-FU concentration profile during
repeated UFT treatment. It would be of potential interest to check
whether the 7-day rest period after the 28-day treatment course
allows or not 5-FU AUC to return to values close to those observed
at the start of treatment.
The clinical pharmacokinetics of capecitabine have been
recently reviewed by Reigner et al (2001). The preferential delivery
of 5-FU into the tissues through the intermediary of thymidine
phosphorylase (TP) is responsible for its much lower presence
(approximately 10 times lower) in plasma than its prodrugs
capecitabine, 50DFCR, 50DFUR or its catabolites FUH2 and FBAL
(Reigner et al, 2001). Reigner et al (2001) noted that the AUC of
capecitabine, 50-DFCR and 50-DFUR did not accumulate in plasma
after long-term administration. We recently conducted a phase I
and pharmacokinetic study of the association of capecitabine–
cisplatin in head and neck cancer patients (Pivot et al, 2003) and
found that there was a significant but moderate increase in
postdose (capecitabine, 1000mgm
 2) AUC values for 50DFUR and
5-FU between day 2 and day 15. Interestingly, these pharmacoki-
netic changes were reversible after the intercycle resting period.
However, more knowledge is still needed about the stability of the
pharmacokinetic parameters of capecitabine and UFT during their
repeated administration.
Perhaps more relevant than plasma pharmacokinetics are data
regarding the fate of anticancer drugs in tumours. In colorectal
patients treated by UFT, Sadahiro et al (2001) examined the
respective concentrations of 5-FU in serum, tumour and normal
mucosa at various intervals after the final dose of UFT. While the
serum 5-FU concentration decreased to very low levels by 24h
following the UFT dose, the intratumour concentration of 5-FU
had been lowered to only about half, and drug levels in normal
mucosa were maintained at least 48h after the final dose.
Concentrations of 5-FU in the normal mucosa were approximately
one-third of those measured in the tumour. Similar observations
had been previously reported in head and neck tumours for
patients pretreated for 1 week with UFT before surgery (Tachibana
et al, 1987). Higher concentrations of 5-FU in tumours were
reported for colorectal cancer patients treated by capecitabine
(Schu ¨ller et al, 2000). Patients received 1225mgm
 2 twice daily
for 5–7 days prior to surgery. The ratio of 5-FU concentrations in
tumour to adjacent healthy tissue averaged 3.2 while the mean
Table 1 Oral fluoropyrimidines under clinical evaluation
Compound Chemical name 5-FU prodrug Effect on DPD
Eniluracil (Glaxo-Wellcome) (Clinical development
currently stopped)
5-Ethynyluracil No Inactivator (complete DPD inhibition)
UFT (Orzel
s, Bristol-Myers Squibb, contains UFT
plus leucovorin)
Uracil+tegafur Yes Inhibitor
S-1 (Bristol-Myers Squibb) 5-Chloro-2, 4
dihydropyrimidine+tegafur+potassium
oxonate
Yes Inhibitor
BOF-A2 (Emitefur
s, Otsuka America
Pharmaceutical)
1-Ethoxymethyl-5-fluorouracil+3-cyano-2,6
dihydropyrimidine
Yes Inhibitor
Capecitabine (Xeloda
s, Roche) N
4-pentyloxycarbonyl-5’-deoxy-5-
fluorocytidine
Yes No DPD inhibitor
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tumour and ranged from 8 to 10 for other tissues. Data in breast
cancer patients treated by capecitabine are more contrasted with
no significant differences for the levels of capecitabine and its
metabolites between healthy and malignant tissue (Mader et al,
2003).
The influence of various covariables including gender, biological
functions, food intake and coadministration of other drugs has
been examined for the pharmacokinetics of oral fluoropyrimi-
dines. Pharmacokinetic changes due to food have been particularly
well studied for UFT and capecitabine. For this latter drug it was
shown by Reigner et al (1998) that food had marked effects on the
AUC of capecitabine only (50% reduction) while the impact on
metabolites in plasma was minor. Consequently, it was recom-
mended that capecitabine be administered with food. In contrast it
was found for UFT that food significantly decreased the maximal
plasma concentrations and AUC values of uracil and 5-FU (Damle
et al, 2001). These observations led to the conclusion not to
administer UFT simultaneously with food. The administration of
food with oral 5-FU and eniluracil has also been considered
(Shepard et al, 2002); the pharmacokinetic data show a slowed
absorption of 5-FU and decreased 5-FU Cmax but without
significant effect on AUC.
The impact of gastrectomy has not been sufficiently explored for
oral fluoropyrimidines. Hirata et al (1999) compared the
pharmacokinetic parameters of 5-FU following administration of
S-1 among patients who underwent gastrectomy and those who did
not. They found that the influence of gastrectomy was minor. Few
studies have considered the possible influence of deteriorated renal
or hepatic functions on the pharmacokinetics of oral fluoropyr-
imidines and more investigations at this level must be encouraged.
This lack of information is surprising as hepatic dysfunction is
relatively common in patients with cancer of the breast, colon or
rectum, which are tumoural localisations with a high incidence of
liver metastases and particularly concerned by the current
development of oral fluoropyrimidines. Twelves et al (1999)
examined the impact of hepatic dysfunction due to liver metastases
on the pharmacokinetics of capecitabine and its metabolites.
Counterintuitively, maximal plasma concentrations and AUC
values of the main metabolites of capecitabine were increased in
patients with liver dysfunction. These differences, however, did not
reach statistical significance and the authors concluded that in
patients with mild-to-moderately impaired hepatic function there
is no need to adjust the dose. Cassidy et al (1999) applied
univariate and multivariate regression analyses to study the
influence of age, gender, body surface area and creatinine
clearance on the main pharmacokinetic parameters of capecitabine
and observed no clinically significant effects, the only statistically
significant results being a higher AUC of intact capecitabine in
females as compared to males (87% greater in females than in
males). However, in patients with renal dysfunction and treated by
capecitabine there was a significant increase in 50DFUR (Poole et al,
2002); this led to specifically recommend a dose modification of
capecitabine for patients with very low creatinine clearance. More
studies are needed to examine the possible influence of altered
renal or hepatic function on the pharmacokinetics of oral
fluoropyrimidines.
PHARMACOKINETICS–PHARMACODYNAMICS
RELATIONSHIPS
For most oral fluoropyrimidines developed so far, PK–PD
relationships were observed most often during phase I trials. For
instance, Van Groeningen et al (2000) noted, for S-1, that among 5-
FU plasma concentrations measured during the 28 days of oral
treatment, only the level just before drug intake in week 2 was
significantly related to grade 3-4 diarrhoea. A confirmation of this
interesting observation during phase II–III trials would be useful
in order to identify a 5-FU threshold concentration at risk for
toxicity with a possibility for dose adjustment during the treatment
course. Steady-state plasma 5-FU concentrations were monitored
during a phase I trial combining eniluracil-5FU treatment with
radiotherapy (Humerickhouse et al, 1999). The authors noted that
average drug concentrations correlated inversely with absolute
neutrophil count nadirs but no correlation was observed with
other toxicities. Muggia et al (1996), during the UFT timed-dose
study, reported on marked toxicities (including life-threatening
haematological toxicities) in patients exhibiting peak levels of 5-FU
above 1mgml
 1.H oet al (2000) observed significant correlations
between maximal plasma concentration or AUC 0–6h of 5-FU and
the occurrence of diarrhoea or nausea and vomiting during a
phase I trial on UFT. This information could be potentially useful
in order to perform an early pharmacokinetic-based dose
adaptation of UFT. Since capecitabine generates 5-FU directly at
cellular level, it can be anticipated that the variability in plasma
pharmacokinetics of capecitabine and metabolite will be of little
concern for pharmacodynamics. This opinion has been confirmed
by clinical pharmacokinetic investigations (Reigner et al, 2001).
PREDICTIVE MARKERS
Whatever the oral fluoropyrimidine considered, all release 5-FU
which is the final cytotoxic prodrug. Consequently, our clinical
knowledge of the predictive markers for 5-FU-based treatment
efficacy should apply to oral fluoropyrimidines. Ichikawa et al
(2003) examined the relative tumoural expression of DPD and TS
for advanced colorectal patients to be treated by UFT. The authors
noted that no responding tumours had both high DPD and high TS
and the response rate reached a satisfactory 75% in tumours with
both low DPD and low TS. Capecitabine ultimately delivers 5-FU at
the cellular level through the action of TP; in theory, the flux of 5-
FU production can be counterbalanced by a more or less marked
opposite flux of 5-FU intracellular catabolism mediated by DPD.
This view was recently confirmed by Tsukamoto et al (2001), who
measured, in vitro, the enzyme kinetic parameters of each of the
enzymes involved in the activation of capecitabine to 5-FU and
elimination. The authors constructed a physiologically based
pharmacokinetic model which revealed that the most important
factors determining the selective production of 5-FU in tumour
tissue after capecitabine administration were activation by TP,
nonlinear elimination of 5-FU by DPD and the tumour blood flow
rate. These data are in agreement with those reported by Ishikawa
et al (1998) showing that the efficacy of capecitabine on a large
panel of 24 human cancer xenografts was significantly correlated
to the tumour TP/DPD ratio. Clinical confirmation of these
experimental data would be of great interest. Overall, our current
understanding of predictive markers for oral fluoropyrimidine
treatment is limited and, with the exception of UFT, remains based
on extrapolations from 5-FU clinical studies.
PHARMACOMODULATION
The first approach for pharmacologically modulating oral
fluoropyrimidines is to incorporate a DPD inhibitor. This strategy
allows 5-FU to be correctly absorbed, as is the case with the
combination eniluracil-5FU (Hirata et al, 1999; Adjei et al, 2002).
DPD inhibition also markedly prolongs 5-FU elimination half-life
thus making the oral administration of fluoropyrimidines phar-
macokinetically acceptable on the basis of two or three daily
intakes. The second approach for a pharmacomodulation of oral
fluoropyrimidines involves combination with leucovorin (LV).
There is, however, an open debate about the clinical/pharmaco-
logical efficacy of LV supplementation during prolonged admin-
istration of 5-FU. Solutions to this dilemma are provided by
Pharmacology of oral fluoropyrimidines
G Milano et al
615
British Journal of Cancer (2004) 91(4), 613–617 & 2004 Cancer Research UKexperimental and clinical data. For instance, an interesting study
by Codacci-Pisanelli et al (1995) examined the effects of adding LV
on human cancer-xenografts in mice subcutaneously implanted
with pellets releasing 5-FU over a period of 3 weeks. The authors
clearly demonstrated that coadministration of LV did not enhance
the therapeutic results. On the clinical side, a meta-analysis was
previously reported showing the advantage of 5-FU plus LV over 5-
FU in terms of objective response rate (Advanced Colorectal
Cancer Meta-analysis Project, 1992). However, all reports included
in the analysis concerned clinical trials with rapid intravenous 5-
FU administrations. A clinical pharmacological study was speci-
fically designed in gastric cancer patients to determine whether
orally administered LV enhanced TS inhibition when added to
UFT (Ichikura et al, 1996). The results showed that TS inhibition
rate in tumours was significantly higher in the UFT–LV group
than in the UFT group alone. However, the data were obtained
following a short period of 3 consecutive days of treatment prior to
surgery. Thus, it is not clear, as is the case with the current clinical
protocols, whether prolonged exposure to UFT results in an
equivalent TS inhibition rate with or without LV supplementation.
On the other hand, Van Cutsem et al (2000) undertook a
randomised phase II trial in advanced colorectal cancer patients
aimed at selecting the most appropriate capecitabine regimen for
testing in phase III studies. Two arms (2 weeks on/1 week off)
differed by the presence or not of daily oral LV. Tumour responses
were comparable between the two arms but more toxicity was seen
in the LV–capecitabine arm. Thus, we do not dispose of strong
experimental and clinical arguments to support LV supplementa-
tion during continuous treatment by oral fluoropyrimidines.
Apart from DPD and LV handling which can apply to most oral
fluoropyrimidines, there are more specifically product-oriented
strategies which can be of potential interest for the pharmacomo-
dulation of these drugs. This is particularly true for UFT and
capecitabine. Reports have been published of attempts to modulate
the activity of 50DFUR, and thus that of capecitabine, through the
upregulation of TP. Cytotoxic agents, particularly taxanes and
irradiation, are able to increase TP activity and result in synergistic
interaction with capecitabine on experimental models in vitro and
in vivo (Sawada et al, 1998, 1999). However, the exact mechanistic
cause of the TP modulation by the cytotoxics has not been clearly
elucidated and indirect effects via the upregulation of TNFa have
been advocated (Sawada et al, 1998, 1999). The preclinical findings
of supra-additive antitumour effects of combining taxanes and
capecitabine have been followed by promising clinical results in
breast cancer treatment with a protocol based on a capecitabine–
docetaxel combination (O’Shaughnessy et al, 2002). Recent
findings suggest that cytochrome P-4502A6 is the major enzyme
responsible for the bioactivation process of ftorafur (Ikeda et al,
2000). Further studies would be of benefit to explore at the tumour
level a possible activation of ftorafur into 5-FU via CYP2A6 and the
possible modulation of this enzymatic pathway.
These possibilities to achieve pharmacomodulation of oral
fluoropyrimidines, notably for UFT and capecitabine, opens up
the prospect of establishing significant novel treatment protocols
based on drug combinations. This increasing number of oral
formulations for several cytotoxic drugs may well make it possible
to provide ‘all oral’ treatments with advantages for patients in
terms of quality of life.
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